X4 Pharmaceuticals Inc. (NASDAQ: XFOR)
$0.71
+0.0054 ( +0.77% ) 1.3M
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Market Data
Open
$0.71
Previous close
$0.70
Volume
1.3M
Market cap
$119.07M
Day range
$0.68 - $0.72
52 week range
$0.53 - $1.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 40 | May 22, 2024 |
8-k | 8K-related | 15 | May 09, 2024 |
10-q | Quarterly Reports | 77 | May 07, 2024 |
8-k | 8K-related | 15 | May 07, 2024 |
ars | Annual reports | 129 | Apr 29, 2024 |
def | Proxies and info statements | 6 | Apr 29, 2024 |
8-k | 8K-related | 40 | Apr 29, 2024 |
8-k | 8K-related | 15 | Apr 29, 2024 |
8-k | 8K-related | 13 | Apr 05, 2024 |
8-k | 8K-related | 13 | Apr 01, 2024 |